Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Lumexa Imaging Holdings, Inc. is a healthcare services company that owns and operates outpatient diagnostic imaging centers across the United States. The company focuses on providing a broad range of medical imaging procedures, including magnetic resonance imaging, computed tomography, positron emission tomography, X-ray, ultrasound, and mammography for both diagnostic and screening purposes. Lumexa Imaging Holdings, Inc. plays a key role in the outpatient care ecosystem by offering advanced imaging capabilities in lower-cost, non-hospital settings, supporting physicians, health systems, and patients with accessible imaging options. Formed in 2018 in partnership with Charlotte Radiology and private equity firm Welsh, Carson, Anderson & Stowe, it has grown into one of the largest national providers of diagnostic imaging services, operating over a hundred centers in multiple states. Headquartered in Raleigh, North Carolina, the company emphasizes clinical quality, state-of-the-art technology, and an integrated platform designed to scale across diverse regional markets.
$12.02
$0.18 (-1.48%)
EOD Aug 14, 2026
Operating margin is thin at 2.61%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 7.8%, steady but not accelerating. Free cash flow declined 149% despite revenue growth, conversion is weakening.
Free cash flow declined 149% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -$6M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$1.02B
▲ +7.8% YoY
Net Income (FY)
-$47M
▲ +49.9% YoY
Op. Margin
2.61%
▲ +4.3pp YoY
ROIC
1.40%
▲ +2.3pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$6M
▼ -149.4% YoY
Op. Cash Flow (FY)
$17M
▼ -21.9% YoY
Net Debt
$904M
Cash & Equiv.
$59M
Continue Research
Lumexa Imaging Holdings (LMRI)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Lumexa Imaging Holdings scores 23/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Lumexa Imaging Holdings scores 23 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 2.6% operating margin and a 1.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh LMRI's valuation and scores 23/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.